Dynamic clinical pathways are essential to keep pace with rapid advancements in oncology treatments and FDA approvals. Inclusive participation and effective communication are vital for pathway ...
Major operational milestone achieved as Incannex advances late-stage development of IHL-42X, with all clinical sites identified and trial infrastructure activatedMELBOURNE, Australia and NEW YORK, May ...
Ryan Haumschild, PharmD, MS, MBA, drives an expert discussion focused on challenges associated with clinical pathway utilization in treating patients with HCC. The panel discussion focused on the ...
Expanding the Multidisciplinary Team in Prediagnostic Care of Lung Cancer: How Else Can We Improve Time to Targeted Treatment in Metastatic Non–Small-Cell Lung Cancer? In the article that accompanies ...
When this is done well, biomarkers accelerate decision-making, reduce uncertainty, and ultimately bring improved therapies to patients faster. When this is done poorly, however, biomarkers can add ...
Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in ...
Lysoway Therapeutics today announced that the first participant has been successfully dosed on May 5, 2026 in the Company’s ...
Edward G. Neilan from NORD discusses critical efforts to speed up therapy development for rare diseases lacking treatments ...
Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) Receipt of previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results